Welcome to the iCAD Investors Page

​iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.

The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".

* See all Press Releases

Recent Events and Webcasts

December 4, 2019
1 pm ET
iCAD Investor Lunch - RSNA 2019: Unmet Medical Need for World-Class Artificial Intelligence Powering Early Cancer Detection

December 5, 2019
9:50 am ET
iCAD to Participate at the Piper Healthcare Conference

November 21, 2019
10 am ET
iCAD to Participate at the Cannacord Genuity Medtech & Diagnostics Forum

October 30, 2019
8:30 am ET
iCAD To Report Third Quarter 2019 Financial Results

© 2019, iCAD Inc.  All rights reserved.  iCAD, the iCAD logo,, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.

​iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy  solutions and services that enable clinicians to find and treat cancers earlier and  while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.